Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Zealand's Living Cell Technologies Cleared For Phase II Diabetes Trials As Pig Herd Becomes More Famous

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Auckland-based Living Cell Technologies received the green light from New Zealand regulators to proceed with Phase II clinical trials of its lead product Diabecell, based on encapsulated pig insulin-producing cells aimed at normalizing blood glucose levels for people with type 1 diabetes

You may also be interested in...



New Zealand's Living Cell Technologies Closer To Getting Pigs To Market

PERTH, Australia - Auckland-based cell implant company Living Cell Technologies has started working on an animal-derived therapeutics project with the New Zealand government's investment promotion agency, Investment New Zealand

New Zealand's Living Cell Technologies Closer To Getting Pigs To Market

PERTH, Australia - Auckland-based cell implant company Living Cell Technologies has started working on an animal-derived therapeutics project with the New Zealand government's investment promotion agency, Investment New Zealand

J&J Subsidiary Centocor Extends Collaboration With New Zealand's Living Cell Technologies For Encapsulation Technology

PERTH, Australia - Johnson & Johnson subsidiary Centocor has extended its two-year research collaboration with New Zealand-based Living Cell Technologies, and signed on for an exclusive two-year option to license globally LCT's encapsulation technology for human cell lines

Related Content

UsernamePublicRestriction

Register

SC074503

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel